Key result
Faster walking speed linked to ~24% lower mortality per 1 km/h in diabetic cardiac patients.
Why the study?
The study aimed to investigate the associations between walking speed and mortality among cardiac patients with type 2 diabetes.
Does higher walking speed reduce all-cause and cardiovascular mortality in cardiac patients with type 2 diabetes?
Cohort (n=490)
No
Does higher walking speed reduce all-cause and cardiovascular mortality in cardiac patients with type 2 diabetes?
Higher walking speed, objectively assessed via a 1 km treadmill test, is a strong independent predictor of reduced all-cause and cardiovascular mortality in cardiac patients with type 2 diabetes.
Supports walking speed for prognosis in cardiac patients with type 2 diabetes; hypothesis-generating, RCTs needed before practice change.
Background: This study aimed to investigate associations between walking speed (WS) and mortality among cardiac patients with type 2 diabetes. Methods: Of the 3328 patients included in the ITER registry between 1998 and 2023, 490 patients diagnosed with type 2 diabetes (mean age 67 ± 9 years) were categorized into tertiles based on WS measured at baseline. Walking speed was measured using the 1 km treadmill walking test (1km-TWT). Cox proportional hazard models were used to examine associations between WS and all-cause and cardiovascular disease mortality, adjusting for demographic and clinical confounders. Results: The results showed a significative inverse association between WS and mortality. A total of 205 patients died over a median follow-up of 11 years. Patients with a higher baseline WS reported a lower mortality risk compared to slow walkers. A similar magnitude was confirmed by the sensitivity analysis excluding people who died in the first three years. Conclusions: The 1km-TWT is an effective predictor of mortality among cardiac patients with type 2 diabetes and a valuable educational tool for exercise-based interventions in secondary prevention. These findings highlight the efficacy of exercise-based programs to improve physical function and reduce mortality risk, underscoring the importance of promoting exercise as part of long-term cardiovascular disease management.
No takes yet. Share an insight, caveat, or question.
Zerbini et al. (2025) conducted a cohort in Stable cardiovascular disease and type 2 diabetes (n=490). Higher walking speed (per 1 km/h increase) vs. Lower walking speed was evaluated on All-cause mortality (HR 0.76, 95% CI 0.67-0.86, p=<0.001). Each 1 km/h increase in walking speed was associated with a 24% reduction in all-cause mortality (HR 0.76) and a 42% reduction in cardiovascular mortality among cardiac patients with type 2 diabetes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: